SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-24-053982
Filing Date
2024-06-20
Accepted
2024-06-20 06:02:52
Documents
16
Period of Report
2024-06-17
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0208074-8k_jasper.htm   iXBRL 8-K 36379
2 PRESS RELEASE DATED JUNE 19, 2024 ea020807401ex99-1_jasper.htm EX-99.1 12727
7 GRAPHIC ex99-1_001.jpg GRAPHIC 6939
  Complete submission text file 0001213900-24-053982.txt   287652

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE jspr-20240617.xsd EX-101.SCH 3928
4 XBRL DEFINITION FILE jspr-20240617_def.xml EX-101.DEF 26833
5 XBRL LABEL FILE jspr-20240617_lab.xml EX-101.LAB 37093
6 XBRL PRESENTATION FILE jspr-20240617_pre.xml EX-101.PRE 25457
19 EXTRACTED XBRL INSTANCE DOCUMENT ea0208074-8k_jasper_htm.xml XML 6109
Mailing Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065
Business Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065 6505491400
Jasper Therapeutics, Inc. (Filer) CIK: 0001788028 (see all company filings)

IRS No.: 842984849 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39138 | Film No.: 241053941
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)